Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-12-01T02:43:17.537Z Has data issue: false hasContentIssue false

Clinical Indicators of Symptom Dimensions and Cognitive Ability in Schizophrenia

Published online by Cambridge University Press:  01 September 2022

L. Farakish*
Affiliation:
Cardiff University, Mrc Centre For Neuropsychiatric Genetics And Genomics, Division Of Psychological Medicine And Clinical Neurosciences, School Of Medicine, Cardiff, United Kingdom
S. Legge
Affiliation:
Cardiff University, Mrc Centre For Neuropsychiatric Genetics And Genomics, Division Of Psychological Medicine And Clinical Neurosciences, School Of Medicine, Cardiff, United Kingdom
M. Owen
Affiliation:
Cardiff University, Mrc Centre For Neuropsychiatric Genetics And Genomics, Division Of Psychological Medicine And Clinical Neurosciences, School Of Medicine, Cardiff, United Kingdom
M. O’Donovan
Affiliation:
Cardiff University, Mrc Centre For Neuropsychiatric Genetics And Genomics, Division Of Psychological Medicine And Clinical Neurosciences, School Of Medicine, Cardiff, United Kingdom
J. Walters
Affiliation:
Cardiff University, Mrc Centre For Neuropsychiatric Genetics And Genomics, Division Of Psychological Medicine And Clinical Neurosciences, School Of Medicine, Cardiff, United Kingdom
A. Cardno
Affiliation:
University of Leeds, Division Of Psychological And Social Medicine, Leeds Institute Of Health Sciences, Faculty Of Medicine And Health, University Of Leeds, Leeds, Uk, Leeds, United Kingdom
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Schizophrenia is a heterogeneous disorder and it is unknown what causes individual variability in symptoms and cognitive ability.

Objectives

To examine the association between nine clinical predictors measurable at the onset of schizophrenia and five phenotype dimensions: positive, negative (diminished expressivity), negative (motivation and pleasure), disorganised symptoms and cognitive ability.

Methods

852 participants (mean age 49 years old) with a diagnosis of schizophrenia or schizoaffective depression were included from the CardiffCOGS cross-sectional sample. Phenotype dimensions were created using confirmatory factor analysis and a 5-factor model. Associations were tested using linear regression, adjusting for age and sex. A Bonferroni correction was applied for (p<1.1x10-3) for multiple testing.

Results

Age of onset of psychosis was significantly associated with positive symptoms (β=-0.18, p=4.0 x10-6). Lower premorbid IQ was associated with diminished expressivity (β=-0.25, p= 7.0x10-13), reduced motivation and pleasure (β=-0.23, p= 4.3x10-11), disorganised symptoms (β=-0.14, p= 7.6x10-5) and reduced cognition (β=0.54, p= 4.8x10-77). Poor premorbid social adjustment held associations with all except positive. Developmental delay was associated with reduced cognition (β=-0.35, p= 4.3x10-5). Cannabis use (year before onset), psychosocial stressors (within 6 months), childhood abuse and family history of schizophrenia held no associations.

Conclusions

Clinical indicators measurable at schizophrenia onset are associated with lifetime symptom variability. A younger psychosis onset is associated with more severe positive symptoms, suggesting possible age-targeted management. Pre-established links of lower premorbid IQ with poor premorbid social adjustment and negative symptom severity with cognition are strengthened. Further investigation could potentially improve diagnosis and guide treatment choice for aspects of schizophrenia with poor outcomes.

Disclosure

No significant relationships.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.